-
Medical journals
- Career
- Contact
Contrast nephropathy and prevention
Authors: V. Teplan 1,2
Authors‘ workplace: Klinika nefrologie Transplantcentra IKEM Praha, přednosta prof. MUDr. Ondřej Viklický, CSc. 1; Subkatedra nefrologie IPVZ Praha, vedoucí prof. MUDr. Vladimír Teplan, DrSc. 2
Published in: Vnitř Lék 2012; 58(7 a 8): 93-96
Category: 80th Birthday MUDr. Miroslav Mydlík, DrSc.
Overview
Contrast-induced nephropathy (CIN) is a serious complication of radio-contrast vascular examination, mainly in high-risk patients with decreased renal function. In prevention, we have to know risk factors strongly influencing follow-up. All potential nephrotoxic drugs should be excluded. We recommend adequate intravenous hydration, supplemented individually with bicarbonate and N-acetylcystein. Studies designed to explore options in CIN prevention included trimetazidine (TMZ) belonging to cytoprotective antiischemic agents used in the treatment of angina pectoris. Trimetazidine affects reperfusion at the cellular and mitochondrial levels, and has antioxidant and metabolic activity via several mechanisms at the cellular level, that is, it shows characteristics making it a clear candidate for CIN prophylaxis. In serious cases hemofiltration could be used to help eliminate contrast solution as soon as posible. Beside serum creatinine, NGAL detected in urine may help in early diagnosis of tubular damage.
Key words:
contrast-induced nephropathy – risk patients – hydratation – trimetazidine – NGAL
Sources
1. Šochman J Poškození ledvin kontrastními látkami. In: Teplan V et al. Akutní poškození a selhání ledvin v klinické medicíně. Praha: Grada 2010 : 303–324.
2. Zemánek D. Kontrastem navozená nefropatie. Cor Vasa 2009; 51 (Suppl 1): 69–73.
3. Onbasili AO, Yeniceriglu Y, Agaoglu P et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart 2007; 93 : 698–702.
4. Mehran R, Nikolsky E Contrastinduced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; 100: S11–S15.
5. Lasser EC, Lyon SG, Berry CC. Reports on contrast media reactions: analysis of data from reports to the US Food and Drug Administration. Radiology 1997; 203 : 605–610.
6. Barrett BJ, Parfrey PS Preventing nephropathy induced by contrast medium. N Engl J Med 2006; 354 : 379–386.
7. McCullough PA, Wolyn R, Rocher LL et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103 : 368–375.
8. Katholi RE, Woods Jr WT, Tailor GJ et al. Oxygen free radicals and contrast nephropathy. AmJ Kidney Dis 1998; 32 : 64–71.
9. Zager RA, Johnson AC, Hanson SY Radiographic contrast mediainduced tubular injury: Evaluation of oxidant stress and plasma membrane integrity. Kidney Int 2003; 64 : 128–139.
10. Rihal CS, Textor SC, Grill DE et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105 : 2259–2264.
11. Caldicott WJ, Hollenberg NK, Abrams HL. Characteristics of response of renal vascular bed to contrast media. Evidence of vasoconstriction induced by reninangiotensin system. Invest Radiol 1970; 5 : 539–547.
12. Russo D, Minutolo R, Cianciaruso B et al. Early effects of contrast media on renal hemodynamics and tubular function in chronic renal failure. J Am Soc Nephrol 1995; 6 : 1451–1458.
13. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. Arch Intern Med 1990; 150 : 1237–1242.
14. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275 : 1489–1494.
15. Bartholomew BA, Harjai KJ, Dukkipati S et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004; 93 : 1515–1519.
16. Lindsay J, Canos DA, Apple S et al. Percutaneous coronary interventionassociated nephropathy foreshadows increased risk of late adverse events in patient with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003; 59 : 338–343.
17. Brar SS, Shen AY, Jorgensen MB et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008; 300 : 1038–1046.
18. Mueller C, Buerkle G, Buettner HJ et al. Prevention of contrast mediaassociated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162 : 329–336.
19. Tepel M, van der Giet M, Schwarzfeld C et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343 : 180–184.
20. Spargias K, Alexopoulos E, Kyrzopoulos S et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation 2004; 110 : 2837–2842.
21. Khanal S, Attallah N, Smith DE et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 18 : 843–849.
22. Stone GW, Mc Cullough P, Tumlin J et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290 : 2284–2291.
23. Marzili M Cardioprotective effects of trimetazidine: a review. Curr Med Res Opin 2003; 19 : 661–672.
24.Teplan V. Možnost prevence kontrastní látkou indukované nefropatie po koronarografii trimetazidinem: příspěvek nefrologa. Cor Vasa 2011; 53 : 1–3.
25. Gunal AI, Celiker H, Ustundag B et al. The effect of oxidative stress inhibition with trimetazidine on the peritoneal alterations induced by hypertonic peritoneal dialysis solution. J Nephrol 2003; 16 : 225–230.
26. Aygen B, Celiker H, Dogukan A et al. The effect of trimetazidine on lipid peroxidation with endstage renal disease. Methods Find Exp Clin Pharmacol 2008; 30 : 757–760.
27. Zoppo A, Faggiotto A, Redaelli L et al. Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patients. Transplantation 1999; 68 : 1211–1215.
28. Singh D, Chopra K. Effect of trimetazidine on ischemia/reperfusion injury in rats. Pharmacol Res 2004; 50 : 623–629.
29. Marenzi G, Marana I, Lauri G et al. The prevention of radio contrast-agent-induced nephropathy by hemofiltration. N Engl J Med 2003; 349 : 1333–1340.
Labels
Diabetology Endocrinology Internal medicine
Article was published inInternal Medicine
2012 Issue 7 a 8-
All articles in this issue
- The Restless Legs Syndrome in patients receiving hemodialysis treatment
- Aldosterone antagonists in chronic heart failure treatment
- Management of stable angina pectoris and of other chronic cardiovascular arterial diseases
- Antiatherogenic effect of HDL subpopulations in patients with newly diagnosed peripheral artery disease
- Sodium concentration in dialysate – an important but neglected parameter in haemodialysis of patients with chronic renal failure
- Oxidative stress and antioxidation systems in haemodialyzed patients
- Pharmacogenetic aspects of treatment with oral antidiabetics
- Refeeding syndrome in a young patient with the anxiety-depressive disorder
- Detecting KRAS and its mutations in biopsy of advanced colorectal carcinoma during colonoscopy
- Aortic stiffness increases central aortic pressure in patients with hypertension
- How to define people at a high risk of pancreatic cancer
- The size of LDL-lipoprotein particles among patient after acute stroke
- Chronic inflammation and the metabolic syndrome
- The prophylaxis and treatment of antiphospholipid syndrome – current options, difficulties and future perspectives
- Advancement in the area of multiple myeloma and development of connected laboratory background
- How to avoid the mistake in diagnosing incipient critical disorder of haemostasis in an out-patient clinic
- Frequencies of the new thrombophilic mutations of antithrombin (SERPINC1) (IVS +141G>A), glycoprotein GPVI (Ser219Pro) and cytochrome CYP4V2 (Lys259Gln) in healthy middle-aged people in Central Bohemia
- Megakaryopoesis and platelet genesis
- Temporary diagnostics and treatment of myeloma bone disease in clinical practice
- Changes to calcium-phosphate metabolism associated with chronic nephropathies
- End stage of chronic kidney disease and metabolic acidosis
- Chronic kidney disease and cellular calcium homeostasis
- To salt or not to salt in kidney diseases? Not more than quantum satis!
- Myocardial infarction the young – our results and experience
- An association between microalbuminuria and obesity in healthy adolescents – preliminary results from the “Respect for Health” study
- Contrast nephropathy and prevention
- Therapeutic approach to the bleeding in association with “old” and “new” anticoagulants
- Diagnosis of heparin-induced thrombocytopenia in the Czech Republic
- Acquired haemophilia A
- High dose treatments and preparatory regimens prior to haematopoietic stem cell transplantation
- Triple combination treatment of chronic hepatitis C
- An anaesthesiologist’s perspective on requirements for pre-surgery examinations
- Fixed combinations in the treatment of hypertension
- Farmacotherapy of hypertension after heart transplantation
- Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and health related quality of life: results from the SHIFT substudies
- Ischemic and non-ischemic causes of ST-segment elevation in patients with chest pain: a systematic review of the literature
- Internal Medicine
- Journal archive
- Current issue
- Online only
- About the journal
Most read in this issue- Myocardial infarction the young – our results and experience
- An anaesthesiologist’s perspective on requirements for pre-surgery examinations
- Megakaryopoesis and platelet genesis
- Aldosterone antagonists in chronic heart failure treatment
Login#ADS_BOTTOM_SCRIPTS#Forgotten passwordEnter the email address that you registered with. We will send you instructions on how to set a new password.
- Career